We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of DexCom (DXCM - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of DXCM and the rest of the Medical group's stocks.
DexCom is one of 894 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. DXCM is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 26.94% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that DXCM has returned about 28.31% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 6.97% on average. This means that DexCom is performing better than its sector in terms of year-to-date returns.
Breaking things down more, DXCM is a member of the Medical - Instruments industry, which includes 94 individual companies and currently sits at #37 in the Zacks Industry Rank. Stocks in this group have lost about 6.58% so far this year, so DXCM is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to DXCM as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of DexCom (DXCM - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of DXCM and the rest of the Medical group's stocks.
DexCom is one of 894 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. DXCM is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 26.94% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that DXCM has returned about 28.31% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 6.97% on average. This means that DexCom is performing better than its sector in terms of year-to-date returns.
Breaking things down more, DXCM is a member of the Medical - Instruments industry, which includes 94 individual companies and currently sits at #37 in the Zacks Industry Rank. Stocks in this group have lost about 6.58% so far this year, so DXCM is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to DXCM as it looks to continue its solid performance.